{"filing":{"accession_number":"0001213900-26-081114","cik":"0001949257","ticker":"RDPTF","company_name":"Radiopharm Theranostics Ltd","form":"6-K","filing_date":"2026-07-24","report_date":"2026-07-24","primary_document":"ea0299158-6k_radiopharm.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1949257/000121390026081114/ea0299158-6k_radiopharm.htm"},"events":[{"id":20283,"run_id":18260,"accession_number":"0001213900-26-081114","anchor_item_number":"EX-99.1","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"The exhibit announces a concurrent registered direct offering of 1,281,646 ADSs (384.5 million ordinary shares) at US$3.16 per ADS for US$4.1 million gross proceeds, plus unregistered warrants and an Australian private placement and share purchase plan totaling up to A$12.7 million. This is a material dilutive equity issuance to accredited institutional investors under Section 4(a)(2) and Regulation D, with warrants exercisable at US$3.79 per ADS expiring July 31, 2029, and options at A$0.018 per option. The offering is subject to shareholder approval at an extraordinary general meeting scheduled for September 11, 2026.","company_name":"Radiopharm Theranostics Ltd","ticker":"RDPTF","filing_date":"2026-07-24","form":"6-K","submitted_at":null,"items":[{"id":19601,"accession_number":"0001213900-26-081114","item_number":"EX-99.1","item_title":"ea029915801ex99-1.htm","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The exhibit announces a concurrent registered direct offering of 1,281,646 ADSs (384.5 million ordinary shares) at US$3.16 per ADS for US$4.1 million gross proceeds, plus unregistered warrants and an Australian private placement and share purchase plan totaling up to A$12.7 million. This is a material dilutive equity issuance to accredited institutional investors under Section 4(a)(2) and Regulation D, with warrants exercisable at US$3.79 per ADS expiring July 31, 2029, and options at A$0.018 per option. The offering is subject to shareholder approval at an extraordinary general meeting scheduled for September 11, 2026.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-24T11:00:38.391897+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":19601,"accession_number":"0001213900-26-081114","item_number":"EX-99.1","item_title":"ea029915801ex99-1.htm","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The exhibit announces a concurrent registered direct offering of 1,281,646 ADSs (384.5 million ordinary shares) at US$3.16 per ADS for US$4.1 million gross proceeds, plus unregistered warrants and an Australian private placement and share purchase plan totaling up to A$12.7 million. This is a material dilutive equity issuance to accredited institutional investors under Section 4(a)(2) and Regulation D, with warrants exercisable at US$3.79 per ADS expiring July 31, 2029, and options at A$0.018 per option. The offering is subject to shareholder approval at an extraordinary general meeting scheduled for September 11, 2026.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-24T11:00:38.391897+00:00","company_name":"Radiopharm Theranostics Ltd","ticker":"RDPTF","filing_date":"2026-07-24"}]}